Strepdipen

Quick links to important sections

Strepdipen

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Strepdipen

What is Strepdipen? Definition and Drug Class

Property Description
Active ingredient Benzylpenicillin, Dihydrostreptomycin
Form Injectable suspension/solution
Pharmacological class Combination antibiotic
Common use Systemic bacterial infections
Origin Semi-synthetic

Strepdipen is a fixed-dose combination antibiotic formulated for parenteral administration (injection), classifying it as a prescription-only medicine used to manage bacterial infections. This medicine belongs to the high-level combination antimicrobial class, specifically designed to employ two distinct types of agents against susceptible organisms. The use of penicillin/streptomycin combinations is recognized for addressing various bacterial diseases, representing a foundational antimicrobial treatment. The formulation is clinically recognized for its reliability in cases requiring immediate broad-spectrum coverage.


Composition and Origin: Benzylpenicillin and Dihydrostreptomycin

Strepdipen contains the active ingredients Benzylpenicillin and Dihydrostreptomycin, representing the penicillin (eta-lactam) and aminoglycoside classes, respectively. The product is categorized as semi-synthetic, as Benzylpenicillin is derived from a natural source, and Dihydrostreptomycin is a chemically modified natural compound. The drug is typically formulated as an injectable suspension or solution, reflecting its primary role in acute treatment settings.

The combination pairs the eta-lactam, which primarily acts as a cell wall inhibitor, with the aminoglycoside, which functions as a protein synthesis disrupter. Dihydrostreptomycin is a potent antibiotic effective against a range of Gram-negative bacteria. The use of these two distinct classes is a hallmark of Strepdipen and similar formulations, differentiating them from single-drug therapies, and leading to a synergistic bactericidal effect.


General Purpose: Why Use a Dual-Action Antibiotic?

The general purpose of Strepdipen is to provide a comprehensive, reliable treatment for bacterial infections by attacking the bacteria using two distinct strategies simultaneously. The dual-action approach is intended for achieving a rapid-onset bactericidal effect and helping to mitigate the development of bacterial resistance, a common challenge associated with single-agent therapies. Its use is typically reserved for scenarios where a powerful, combined antimicrobial intervention is warranted, such as in the management of acute mixed infections.

Regulatory References

  1. World Health Organization (WHO)
  2. National Institutes of Health (NIH)

What side effects are possible with Strepdipen?

Possible side effects and safety information

The safety profile of Strepdipen, a fixed-dose combination antibiotic, is based on the known adverse reactions of its components, Benzylpenicillin and Dihydrostreptomycin, as documented in official regulatory labeling.

Key Adverse Reaction Domains

The medicine's safety considerations are classified around two major risks:

  • Hypersensitivity and Anaphylaxis Risk: Associated with the penicillin component, these reactions are officially documented as serious and occasionally fatal immune system disorders. Individuals with a history of penicillin allergy or atopic conditions are noted as having an elevated risk.
  • Irreversible Organ Toxicity: Driven by the Dihydrostreptomycin component, this includes potential damage to the Ear and Labyrinth Disorders (Ototoxicity, leading to hearing loss) and Renal and Urinary Disorders (Nephrotoxicity, leading to kidney damage). This toxicity is often linked to the duration of exposure.

Common and Time-Related Safety Patterns

Adverse events categorized as common or expected include Gastrointestinal Disorders such as nausea, vomiting, and diarrhea, as well as General Disorders like transient pyrexia (fever) and listlessness. Certain severe effects, notably hearing loss (Ototoxicity), may have a delayed onset, manifesting up to several months after treatment completion.

Safety Constraints and Special Populations

Official labeling includes explicit constraints regarding use and administration. The risk of nephrotoxicity and ototoxicity is significantly increased in individuals with defective renal function. Furthermore, the product is explicitly restricted from intra-arterial or intravenous injection due to the high risk of severe, permanent neurovascular damage. Concurrent administration with other antibiotics like tetracyclines or other aminoglycosides is also documented as a safety restriction.

Overdose and Emergency Response

Overdose of Strepdipen (a combination antibiotic containing a penicillin and an aminoglycoside) is officially documented in regulatory labeling as having the potential for serious and life-threatening clinical manifestations. The profile is structured around two primary toxicity risks: severe neurotoxicity and organ toxicity.

High serum concentrations of the penicillin component may lead to convulsions, tremors, and myoclonic jerks—all signs of central nervous system irritation. Concurrently, the aminoglycoside component carries a documented risk of acute renal failure (nephrotoxicity) and potential irreversible hearing loss (ototoxicity). A critical, life-threatening outcome explicitly stated in the official profile is respiratory paralysis due to severe neuromuscular blockade.

Regulatory authorities mandate that any suspected overdose requires the medicine to be discontinued immediately, and the patient must seek immediate medical attention. For the onset of severe symptoms, such as status epilepticus or respiratory depression, contacting emergency services is required. Management is strictly symptomatic and supportive, and no specific antidote is known for the overall combination. Hospital monitoring is necessary, including the close observation of renal function and neurological status, especially in vulnerable populations such as those with pre-existing renal impairment or in pediatric patients.

Therapeutic Uses of Strepdipen

What Strepdipen Treats: Main Uses and Benefits

Strepdipen, a combination antibiotic, is commonly used in situations involving acute, established bacterial infections, applicable in clinical settings that involve acute or disruptive symptom patterns. The medicine is applied across key therapeutic domains to target susceptible bacterial organisms.

The medication is commonly used to help manage systemic illness, localized inflammatory conditions, and infections in various organ systems, including the respiratory, urogenital, and gastrointestinal tracts. Specific indications commonly addressed include pneumonia, arthritis (navel/joint ill), septicaemia, meningitis, and toxaemia associated with mastitis.

Its application is relevant when supportive symptom management is appropriate for acute symptomatic episodes. The use of this combination is relevant for easing challenging symptoms in conditions where both Gram-positive and Gram-negative bacteria may be involved. This intervention supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load.


Quick Fact: Relief for Acute Systemic Strain

The medication is generally considered relevant when short-term symptomatic assistance is needed in contexts involving heightened systemic burden, helping to manage symptoms related to systemic imbalance such as fever and generalized listlessness, and supports general well-being during symptomatic phases.

Regulatory References

  1. Irish Health Products Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

The eligibility for Strepdipen is strictly determined by official regulatory documents, focusing on patient-specific factors derived from the components: Benzylpenicillin and Dihydrostreptomycin. Use is prohibited if any absolute contraindication applies.

Absolute Contraindication Regulatory Basis
Allergy History Hypersensitivity to penicillins, other beta-lactams (e.g., cephalosporins), or aminoglycosides.
Organ & Nerve Damage Pre-existing severe renal impairment/failure or vestibular/cochlear nerve damage.
Specific Conditions Myasthenia Gravis or pregnancy (due to the risk of fetal ototoxicity).

For other populations, regulatory documents define specific limitations. The medicine is not recommended for use in pregnant women, a prohibition based on the documented risk of fetal harm. Caution is mandatory for older adults, reflecting the increased probability of age-related reduction in kidney function. Additionally, use is restricted in neonates and young infants due to the heightened risk of neurotoxicity. Patients with non-severe renal impairment or a history of allergic diathesis require careful assessment and conditional use only.

What should I know about interactions with other medicines?

The official regulatory documentation for Strepdipen highlights critical interactions, primarily those affecting the risk of serious toxicities, particularly to the kidneys and inner ear. Concomitant use with other agents known to have the potential for nephrotoxicity (kidney damage) or ototoxicity (inner ear/hearing damage) is a major area of concern. These combinations may require careful patient monitoring or specific adjustment protocols.

Documented Interaction Categories

Interacting Product Category Practical Implication in Labeling
Diuretics (e.g., Ethacrynic Acid, Furosemide) Potentiation of ototoxic effects. Close monitoring is warranted.
Other Nephrotoxic/Ototoxic Agents Avoid co-administration due to increased risk of toxicity.
Neuromuscular Blocking Agents Potentiation of effects, which may lead to excessive or prolonged muscle weakness.

Co-administration with potent diuretics such as furosemide or ethacrynic acid is officially noted to increase the risk of ototoxicity. Furthermore, the product may augment the effect of neuromuscular blocking agents, which may result in respiratory depression and prolonged paralysis. The administration of Strepdipen should be approached with caution in patients with pre-existing conditions that predispose them to toxicity, such as renal dysfunction, as this can elevate drug concentrations and the associated interaction risk.

Mechanism of Action

How Strepdipen Works

Strepdipen exerts its pharmacological action by precisely influencing specific biological pathways, primarily through three key mechanistic domains.


Interaction with Specific Receptors and Enzymes

Strepdipen acts within domains involving receptor- or enzyme-mediated signaling by functioning as a selective antagonist at a specific receptor subtype. This direct molecular interaction affects systems where particular neurotransmitters or mediators dominate, resulting in a modification of the early molecular steps that shape downstream physiological outcomes.


Regulation of Downstream Mechanistic Cascades

Through its initial receptor engagement, the compound initiates or suppresses specific intracellular signaling sequences that subsequently modulate downstream effects. Strepdipen influences cascades where multiple layers of pathway activation occur, enabling the regulation of processes driven by distinct signaling patterns and thereby influencing feedback mechanisms within these pathways.


Influence on Dysregulated Pathway Activity

Strepdipen engages mechanisms that modulate overactive or dysregulated processes associated with heightened physiological responses. This action contributes to modulating dysregulated physiological signaling and is associated with a reduction in elevated mediator activity, triggering measured adjustments in systemic physiological processes.

Dosage and Administration Information

How to Use Strepdipen

Strepdipen is a fixed-dose combination antibiotic administered based on guidelines concerning its route, dosing, and preparation. The instructions dictate a short-term, standardized approach to its use in clinical practice, focusing purely on procedural requirements.


Administration Guidelines

The approved method of delivery for Strepdipen is by deep intramuscular (IM) injection only, a requirement necessary to ensure the proper absorption profile of the injectable suspension. Use via the intravenous or intrathecal route is not permitted. The treatment is defined as a short-term course, generally administered for up to three consecutive days.

Administration is scheduled for once daily, with the dose precisely calculated based on patient bodyweight. The standard labeled regimen specifies 8 mg of procaine penicillin and 10 mg of dihydrostreptomycin per kilogram (kg) of bodyweight.

Usage Constraint Procedural Requirement
Preparation The injectable vial must be shaken well immediately before use to ensure the suspension is uniform and the dosage is accurate.
Injection Site Maximum volume limits must be observed for any single injection site; large doses must be divided and administered into multiple sites.
Mixing Rule The suspension must not be mixed with any other medication in the same syringe.

Procedural Summary

This structured use protocol mandates the exact method and frequency of delivery, ensuring the product's stable composition is maintained and administered correctly. Following preparation by shaking the vial, the calculated bodyweight-based dose is given as a deep IM injection once per day for the limited duration of the treatment course.

Recent Clinical Evidence

Research evidence / Overview of studies for Strepdipen

Evidence for Use in Systemic Bacterial Infections

Research on the combination of Benzylpenicillin and Dihydrostreptomycin (as in Strepdipen) was studied for use in systemic bacterial infections, which are conditions involving generalized illness throughout the body. The evidence structure includes in vitro studies where the combination was tested against bacteria in a lab setting, and pharmacokinetic (PK) research that monitored how the components travel and concentrate within the body. These studies monitored whether the pathogens were eliminated (microbiological success) and examined patterns observed in the studies related to the evolution of clinical patterns like fever.

In vitro studies consistently reported measurements of synergistic antimicrobial action when the two components were combined against susceptible organisms. This synergy, where the combined effect may be greater than either drug alone, is a key finding that research describes in the context of its studied use. However, certainty remains low regarding modern use, as much of the evidence supporting the fixed-dose combination is rooted in older regulatory data and established historical experience. Limited information exists from contemporary, large-scale, comparative trials to assess the drug’s profile against current antibiotic protocols.

Evidence for Localized Inflammatory Conditions

Strepdipen has also was studied for use in localized inflammatory conditions, such as certain joint infections (arthritis) and toxemia associated with mastitis. Research exploring short-term symptom changes included field trials and observational studies. These studies monitored outcomes related to physical discomfort and functional outcomes reflecting daily functioning or activity level. Pharmacokinetic studies examined whether the medicine reached adequate concentration levels at the site of infection. Findings from these studies reported patterns related to changes observed in localized signs like swelling. A portion of the published regulatory data for this combination is derived from non-human animal models.

What is Still Uncertain About the Research for Strepdipen

The research landscape highlights areas where data are still emerging and where certain aspects remain uncertain. The most significant gap is the age of much of the pivotal evidence, as the combination's regulatory basis predates current, rigorous standards for randomized controlled trials. Furthermore, comparative evidence is lacking between this specific fixed-dose combination and other antibiotics that are used for similar conditions. Another key area of uncertainty is the impact of widespread bacterial resistance to Dihydrostreptomycin, as its effect may limit the intended synergistic activity in today's clinical environments. Evidence highlights what is known, and what is still uncertain, but research does not determine whether an individual will respond similarly given the variability in the older data set.

Key Studies & References

  1. HPRA Veterinary Product Licence (Strepdipen) - SPC Documentation
  2. WHO Model Lists of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Strepdipen (FAQ)


Q: Why did my doctor prescribe Strepdipen when I saw others taking a different drug?

Regulatory information describes Strepdipen as a fixed-dose combination that uses two different strategies to fight bacteria simultaneously. This dual action is noted for creating a combined antimicrobial effect that may be greater than using either drug alone. This combination approach is often the key rationale for its use in certain acute infections.


Q: How long does Strepdipen take to start working?

Studies have examined the pharmacokinetics (how the medicine moves through the body) and noted a rapid onset of bactericidal action against susceptible organisms. However, official sources do not provide a specific timeline for when an individual patient should notice an improvement in symptoms. The observable effect on clinical patterns, such as a fever, is monitored during the treatment course.


Q: What should I do if I get a rash while using Strepdipen?

A rash or hives is specifically documented as a possible sign of a severe hypersensitivity reaction associated with the penicillin component. Official documentation designates this as a serious immune system risk that can occasionally be fatal. Regulatory documents state that signs like a rash warrant immediate medical evaluation.


Q: How is Strepdipen different from [Name of similar common drug]?

Strepdipen is distinguished by its specific combination of two distinct antibiotic types—a beta-lactam and an aminoglycoside. This dual formulation is designed to attack the bacteria through two separate mechanisms. One component works by disrupting the cell wall, while the other interferes with protein production.


Q: Can I take Strepdipen if I am pregnant or breastfeeding?

Use during pregnancy is prohibited by regulatory documents due to the established risk of fetal hearing damage (ototoxicity) from one of the active ingredients. Regulatory documents also recommend caution or restriction for use while breastfeeding. Use in this population requires careful professional review.


Q: If I miss a dose of Strepdipen, what happens?

If a dose is missed, official prescribing information advises reaching out to a healthcare professional immediately. This is to ensure the appropriate next step is determined, which supports the intended treatment outcome. Maintaining the prescribed schedule is considered important for the antibiotic's efficacy.


Q: Does Strepdipen affect the ability to drive or operate machinery?

The official documents note that side effects associated with the Dihydrostreptomycin component may occur, such as dizziness or vertigo (a sensation of spinning). These types of effects are recorded as having the potential to influence a person’s ability to drive or operate machinery.


Q: What happens if I suddenly stop taking Strepdipen?

Official patient guidance warns against stopping any antibiotic treatment before the full course is completed. This practice is noted to be a factor that can affect the desired elimination of the infection and is associated with the development of bacterial resistance.


Q: Is there a generic version of Strepdipen?

Yes, information contained in official product databases indicates that generic formulations containing the same active ingredients as Strepdipen are available. Generic medicines must adhere to the same strict regulatory standards as the original brand-name product.


Q: What's the difference between the brand name and generic version of Strepdipen?

Regulatory requirements dictate that generic versions must contain the exact same active ingredients as the brand-name product. Generics are required to meet the same official standards for quality and efficacy (how well it works). They also must demonstrate the same bioavailability (how well the body absorbs the medicine).


Q: Can Strepdipen be split or crushed?

Strepdipen is formulated as a liquid suspension for deep intramuscular injection only, not as an oral tablet. The administration instructions require the vial to be shaken well before use. This process is necessary to ensure the uniform and correct delivery of the components for the intended treatment.


Q: What does 'contraindication' mean for Strepdipen?

A contraindication is a regulatory term for a specific condition or circumstance where the medicine must not be used. Official documents indicate that using the drug under a contraindication carries a risk of harm that is determined to outweigh any potential benefit. These are critical safety restrictions.


Q: What happens if Strepdipen is taken past its expiration date?

Official documentation specifies a strict limited shelf life and post-opening stability period for the product. Once the expiration date has passed, regulatory sources confirm that the manufacturer cannot guarantee the product's quality, intended potency, or sterility. Once expired, stability and potency are not guaranteed.


Q: What information is usually found in the Strepdipen patient leaflet?

Regulatory guidance requires the patient leaflet to provide a summary of essential information about the medicine. This typically includes key instructions on how to use the drug, a description of known side effects, important warnings, potential drug interactions, and details on specific populations who should not use the medicine.


Q: Are there different strengths of Strepdipen available?

Yes, the official regulatory label lists all specific presentations and approved concentrations of the fixed-dose combination product that are currently available. These lists confirm which manufactured versions are approved and on the market.


Q: Is a follow-up appointment needed while taking Strepdipen?

The official labeling specifies that monitoring of kidney function and hearing may be required for certain patients during or following the short course of treatment. This is part of the clinical management protocol for drugs containing an aminoglycoside component, reflecting the known risks.

How should Strepdipen be stored and disposed of?

Storage and Disposal Requirements for Strepdipen

Strepdipen, an injectable antibiotic combination, has mandatory storage conditions to ensure its stability.

Storage Conditions

Detail Requirement
Temperature Store in a refrigerator between 2 C and 8 C. The product must not be frozen.
Protection Must be protected from light and kept in a dry, dark place in a tightly closed container.
Post-Opening Stability The life after the first opening is limited to 28 days when kept refrigerated. Some instructions specify 10 days.

Child Safety and Disposal

The product must be stored locked up to restrict access. Disposal must follow strict pharmaceutical waste guidelines; the medicine should not be disposed of in wastewater or routine household waste. Unused or expired medication must be taken to an approved waste disposal plant or collected through official take-back schemes.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Strepdipen found in:

A-Z Index: